immunoglobulin A nephropathy


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

immunoglobulin A nephropathy

Abbreviation: IgA n
A form of glomerulonephritis in which immunoglobulin A molecules are deposited in the glomeruli. The disease, more common in boys than girls, may eventually cause renal failure in as many as 40% of patients. It is treated with glucocorticoids.
Synonym: Berger disease See: glomerulonephritis
See also: nephropathy
References in periodicals archive ?
Association of single nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients.
Immunoglobulin A nephropathy (IgAN) is the most prevalent primary chronic glomerular disease worldwide.[sup][1] In China, IgAN accounts for 33.19% of total renal biopsy diagnoses and 45.26% of primary glomerular diseases.[sup][2] Approximately 10% of IgAN patients demonstrate an accelerated loss of renal function and 30–40% slowly progress to renal failure;[sup][3] however, proteinuria control can improve the prognoses for IgAN.[sup][4] Pathogenesis and progression of IgAN are related to many factors, including heredity, inflammation, renin-angiotensin system activity, extracellular matrix metabolism, and abnormal blood coagulation.[sup][5],[6] An effective delay or blockade of IgAN progression may require multiple treatments.
Association of a single nucleotide polymorphism in the immunoglobulin mu-binding protein 2 gene with immunoglobulin A nephropathy. J.
Phase 3 clinical programs are in progress for OMS721 in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A nephropathy, and in atypical hemolytic uremic syndrome.
Omeros announced the formation of an independent Academic Leadership Committee to support its Phase 3 clinical program for OMS721 in immunoglobulin A nephropathy. The committee will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
Phase 3 clinical programmes are in progress for OMS721 in atypical hemolytic uremic syndrome, in immunoglobulin A nephropathy and in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).